153 related articles for article (PubMed ID: 35526519)
21. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Seidel C; von Bueren AO; Bojko S; Hoffmann M; Pietsch T; Gielen GH; Warmuth-Metz M; Bison B; Kortmann RD; Kramm CM
Strahlenther Onkol; 2018 Mar; 194(3):215-224. PubMed ID: 29022050
[TBL] [Abstract][Full Text] [Related]
22. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
[TBL] [Abstract][Full Text] [Related]
23. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
24. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
[TBL] [Abstract][Full Text] [Related]
25. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
26. Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor.
Zepecki JP; Snyder KM; Moreno MM; Fajardo E; Fiser A; Ness J; Sarkar A; Toms SA; Tapinos N
Oncogene; 2019 Mar; 38(10):1734-1750. PubMed ID: 30353164
[TBL] [Abstract][Full Text] [Related]
27. The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells.
Tai PA; Liu YL; Wen YT; Lin CM; Huynh TT; Hsiao M; Wu ATH; Wei L
Mol Imaging; 2019; 18():1536012119870899. PubMed ID: 31478435
[TBL] [Abstract][Full Text] [Related]
28. Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Gött H; Kiez S; Dohmen H; Kolodziej M; Stein M
Childs Nerv Syst; 2022 Sep; 38(9):1791-1796. PubMed ID: 35181800
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Blumenthal DT; Dvir A; Lossos A; Tzuk-Shina T; Lior T; Limon D; Yust-Katz S; Lokiec A; Ram Z; Ross JS; Ali SM; Yair R; Soussan-Gutman L; Bokstein F
J Neurooncol; 2016 Oct; 130(1):211-219. PubMed ID: 27531351
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in a Child with
Bagchi A; Orr BA; Campagne O; Dhanda S; Nair S; Tran Q; Christensen AM; Gajjar A; Furtado LV; Vasilyeva A; Boop F; Stewart C; Robinson GW
N Engl J Med; 2021 Aug; 385(8):761-763. PubMed ID: 34407349
[No Abstract] [Full Text] [Related]
31. Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report.
Tadipatri R; Eschbacher J; Fonkem E; Kresl J; Azadi A
Cureus; 2022 Nov; 14(11):e31449. PubMed ID: 36523718
[TBL] [Abstract][Full Text] [Related]
32. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
[TBL] [Abstract][Full Text] [Related]
33. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
34. Histone-mutant glioma presenting as diffuse leptomeningeal disease.
Nadkarni T; Hamilton K; Niazi F; Ward M; Okakpu U; Castellani RJ; Prisneac I; Sener U
CNS Oncol; 2021 Sep; 10(3):CNS75. PubMed ID: 34469205
[TBL] [Abstract][Full Text] [Related]
35. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
36. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D
Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293
[TBL] [Abstract][Full Text] [Related]
37. Larotrectinib: A Targeted Therapy for Solid Tumors.
Mota-George G; Schneider SM
Clin J Oncol Nurs; 2021 Apr; 25(2):181-187. PubMed ID: 33739345
[TBL] [Abstract][Full Text] [Related]
38. Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.
Zhou W; Chen C; Shi Y; Wu Q; Gimple RC; Fang X; Huang Z; Zhai K; Ke SQ; Ping YF; Feng H; Rich JN; Yu JS; Bao S; Bian XW
Cell Stem Cell; 2017 Nov; 21(5):591-603.e4. PubMed ID: 29100012
[TBL] [Abstract][Full Text] [Related]
39. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
40. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
